Myomo (NYSEAMERICAN:MYO – Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Myomo to post earnings of ($0.08) per share and revenue of $11.51 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.
Myomo (NYSEAMERICAN:MYO – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. Myomo had a negative return on equity of 138.85% and a negative net margin of 33.53%. The company had revenue of $11.70 million for the quarter, compared to analysts’ expectations of $10.35 million. On average, analysts expect Myomo to post ($0.32) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.
Myomo Stock Performance
Myomo stock opened at $1.24 on Monday. Myomo has a fifty-two week low of $0.60 and a fifty-two week high of $1.89. The company has a debt-to-equity ratio of 1.98, a quick ratio of 2.01 and a current ratio of 2.31. The company has a market capitalization of $49.12 million, a PE ratio of -3.65 and a beta of 1.74. The company has a 50 day moving average price of $1.42 and a 200-day moving average price of $1.08.
Insider Buying and Selling at Myomo
In related news, insider Harry Kovelman sold 17,250 shares of Myomo stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $1.73, for a total value of $29,842.50. Following the sale, the insider owned 105,983 shares of the company’s stock, valued at approximately $183,350.59. This trade represents a 14.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 47,738 shares of company stock valued at $70,662 in the last three months. Corporate insiders own 12.14% of the company’s stock.
Myomo Company Profile
Myomo, Inc is a medical device company that develops and markets wearable robotic braces designed to help individuals with impaired upper-limb function regain movement and perform activities of daily living. Its principal product is the MyoPro, a lightweight, electrically powered orthosis that detects a user’s residual muscle signals and assists movement of the arm and hand.
The MyoPro is intended for people affected by neuromuscular disorders and injuries, including stroke, brachial plexus injury, multiple sclerosis, traumatic brain injury and spinal cord injury.
Featured Stories
- Five stocks we like better than Myomo
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.
